 |
From my Message board« on: Today at 03:23:43 AM »
|
UPDATE 2-Lexicon diabetes drug meets mid-stage trial goal
BANGALORE, Jan 20 (Reuters) – Lexicon Pharmaceuticals Inc said its experimental diabetes drug met the main goals of a mid-stage trial, sending its shares soaring 46 percent in morning trade.
Data from the mid-stage study of the drug, LX4211, showed improvements in glycemic control, suggesting statistical significance in the primary and multiple secondary efficacy goals, the company said.
“Today’s results lay down the foundation for partnership talks … the primary care diabetes market is a huge opportunity for the company and they will have to partner the drug to send it across the finish line,” Thomas Weisel Partners analyst Stephen Willey said by phone.
The company said it was already in discussions with potential partners for the drug, adding that there were some awaiting the trial results.
And on Jan 26th this cane out
Lexicon to Host Conference Call and Webcast to Review Top-Line Phase 2 Results …
THE WOODLANDS, Texas, Jan. 26 /PRNewswire-FirstCall/ — Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) will hold a conference call on Thursday, January 28, 2010 at 11:30 am Eastern Time to discuss its recent top-line Phase 2 clinical results with LX4211, Lexicon’s once-per-day, orally-delivered, small molecule drug candidate for the treatment of type 2 diabetes mellitus.
The dial-in number for the conference call is 888-220-1244 (within the US/Canada) or 706-679-5615 (international). The conference ID for all callers is 53373071. Investors can access a live webcast of the call at www.lexpharma.com. An archived version of the webcast will be available on the website.
About Lexicon
Lexicon is a biopharmaceutical company focused on discovering and developing breakthrough treatments for human disease. Lexicon currently has five drug candidates in development for diabetes, autoimmune disease, carcinoid syndrome, glaucoma and irritable bowel syndrome, all of which were discovered by Lexicon’s research team. Lexicon has used its proprietary gene knockout technology to identify more than 100 promising drug targets. Lexicon has focused drug discovery efforts on these biologically-validated targets to create its extensive pipeline of clinical and preclinical programs. For additional information about Lexicon and its programs, please visit www.lexpharma.com.
{ 1 comment… read it below or add one }
If they announce a partnership agreement with any major co this will be very big.